İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2025 · article

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial

ISSN0732-183X
YÖKSİS OpenAlex Açık erişim · hybrid Üst %1
Yıl2025
Atıf22OpenAlex
Atıf31Semantic Scholar · 2 etkili
Yüzdelik%99,6
FWCI15,821,00 = dünya ortalaması
Scopus (SJR)Q1
WoS (JCR)Q1

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıJournal of Clinical Oncology
  • Katalog eşleşmesi (ISSN)Journal of Clinical Oncology
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

PURPOSE Prognosis for patients with refractory/relapsed large B-cell lymphoma (LBCL) considered ineligible for curative-intent therapy is poor. The combination of mosunetuzumab, a T-cell–engaging bispecific antibody, and polatuzumab vedotin, an antibody-drug conjugate (Mosun-Pola), represents a novel fixed-duration outpatient therapy. METHODS In the phase III SUNMO trial, patients with refractory/relapsed LBCL who were ineligible for autologous stem-cell transplant were randomly assigned (2:1) to receive Mosun-Pola or rituximab, gemcitabine, and oxaliplatin (R-GemOx). Dual primary end points were centrally assessed overall response rate (ORR) and progression-free survival (PFS). Overall survival was a key secondary end point. RESULTS A total of 208 patients were randomly assigned to receive Mosun-Pola (n = 138) or R-GemOx (n = 70). At a median follow-up of 23.2 months, the primary analysis of SUNMO demonstrated that the median PFS was significantly longer with Mosun-Pola than with R-GemOx (11.5 months [95% CI, 5.6 to 18] v 3.8 months [95% CI, 2.9 to 4.1]; hazard ratio for progression or death, 0.41 [95% CI, 0.3 to 0.6]; P < .0001). ORR was significantly greater with Mosun-Pola versus R-GemOx (70% v 40%; P < .0001), with complete response rates of 51% and 24%, respectively. In the Mosun-Pola group, the rate of grade ≥2 cytokine release syndrome (CRS) and usage of tocilizumab occurred in <5% of patients and patient-reported outcomes were improved compared with R-GemOx. CONCLUSION Mosun-Pola demonstrated superior efficacy versus R-GemOx, with significant improvements in both ORR and PFS, and infrequent CRS events with a manageable safety profile.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

22atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yazarlar

28
  1. Lihua E Budde 1
  2. Huilai Zhang 2
  3. Won-Seog Kim 3
  4. Dai Maruyama 4
  5. Eduardo M Rego 5
  6. Lalita Norasetthada 6
  7. Huangming Hong 7
  8. MUHİT ÖZCAN ANKARA ÜNİVERSİTESİ 8
  9. Young-Woo Jeon 9
  10. Danielle Leão Cordeiro de Farias 10
  11. Laura Maria Fogliatto 11
  12. Astrid Pavlovsky 12
  13. Hideki Goto 13
  14. Adam J Olszewski 14
  15. Nikesh Shah 15
  16. Bei Hu 16
  17. Shen Yin 17
  18. Hao Wu 18
  19. Iris To 19
  20. Wahib S Ead 20
  21. Joan Ashby 21
  22. Martin Janousek 22
  23. Song Pham 23
  24. Jue Wang 24
  25. Antonia Kwan 25
  26. Connie L Batlevi 26
  27. Michael C Wei 27
  28. Jason Westin 28